Why this growth stock could soar 40%+ within 2 years

Stunning gains could be on the horizon for this company.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Healthcare continues to be a rapidly growing sector. An increasing world population which is also ageing provides a tailwind for sales and profitability across a range of healthcare stocks. As such, share price gains could be ahead for companies operating within the industry. Reporting today is one such stock which could record a capital gain of 40% by 2019.

Improving performance

Georgia Healthcare Group (LSE: GHG) is a dominant company in its local market. In fact, it is the largest healthcare services provider, the third largest pharmaceutical retailer and wholesaler, and the largest medical insurance provider in the East European country. As such, its business is relatively well diversified between the three different divisions.

In the 2016 financial year, it was able to record strong results despite a swing to a loss in its medical insurance division. The loss came after a more challenging year, with one large corporate insurance contract having expired and not been renewed. Despite this, its overall performance was strong. Its sales and pre-tax profit increase by over 70%. Furthermore, it remains on target to deliver a more than doubling of its Healthcare Services revenue by 2018 compared to its 2015 level.

Growth outlook

The sharp rise in sales is set to be translated into rising earnings for the company. In 2017, Georgia Healthcare’s bottom line is forecast to rise by 37%, followed by 40% growth in 2018. Despite this strong growth rate, the company’s shares trade on a price-to-earnings growth (PEG) ratio of 0.8. Therefore, if they were to rise in price by 40% they would trade on a PEG ratio of just over 1, which would suggest fair value for money. Certainly, a higher valuation is possible, but a margin of safety may be required due to the company’s lack of geographical, rather than product, diversification.

As mentioned, the healthcare sector could offer strong growth prospects. As such, a number of other companies within the sector may also be worth buying at the present time. For example, Hikma Pharmaceuticals (LSE: HIK) is forecast to record a rise in its bottom line of 37% this year, followed by further growth of 29% next year. This puts it on a PEG ratio of just 0.7, which indicates that it offers superior value for money when compared to Georgia Healthcare.

Risk factor

In addition, Hikma may be a lower-risk business than its healthcare peer. It operates across the globe and so is not dependent on changes in regulations or trading conditions in one country. Hikma has a well-diversified product portfolio, with its focus on generics arguably providing a degree of consistency which some of its healthcare peers lack.

While the developing world may be emerging from a period of austerity, the cost of treatment for an ageing population may become difficult to afford. Therefore, generics may have a more pivotal role to play in future healthcare requirements, with a growing world population also likely to make them increasingly popular. As such, Hikma appears to be a sound buy, with a lower valuation and greater diversity making it a superior option to even the 40%-plus gains which seem to be on offer through Georgia Healthcare.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Peter Stephens has no position in any shares mentioned. The Motley Fool UK has recommended Hikma Pharmaceuticals. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Illustration of flames over a black background
Small-Cap Shares

This 13p penny stock’s on fire! Should I buy it?

This UK penny stock has been making investors a lot of money in recent months. Is it worth buying today…

Read more »

Investing Articles

Am I missing out by not buying FTSE bank gem Standard Chartered?

Despite its recent price rise, FTSE 100 bank Standard Chartered still looks very undervalued against its peers and appears set…

Read more »

Mature black couple enjoying shopping together in UK high street
Investing Articles

£10k to invest in an ISA? Here’s how I’d use it to aim for a £97k annual passive income

Harvey Jones reckons he can build a high and rising passive income by investing in a spread of high-yielding FTSE…

Read more »

BUY AND HOLD spelled in letters on top of a pile of books. Alongside is a piggy bank in glasses. Buy and hold is a popular long term stock and shares strategy.
Investing Articles

Dividend giant Legal & General’s share price still looks cheap, so should I buy more?

Legal & General’s share price still looks undervalued to me, with the company set for strong growth and continuing to…

Read more »

Two white male workmen working on site at an oil rig
Investing Articles

Up 32% this month! Is it finally time to buy this falling FTSE 250 stock?

After years of consistent losses that have slashed the share price in half, this troubled FTSE 250 stock’s making sudden…

Read more »

Chalkboard representation of risk versus reward on a pair of scales
Growth Shares

Could the Rolls-Royce share price be above 500p by the year end?

Jon Smith questions whether the Rolls-Royce share price could push higher if upcoming results look good, but balances it out…

Read more »

Young Caucasian man making doubtful face at camera
Investing Articles

One dirt cheap income stock I’d buy in an ISA today and it’s not Imperial Brands or Vodafone

Harvey Jones is on the hunt for a top FTSE 100 income stock at a low price. He's ruled out…

Read more »

Happy young female stock-picker in a cafe
Investing Articles

£20,000 in savings? Here’s how I’d try to turn it into a £2,987 monthly passive income

Investing in FTSE 100 and FTSE 250 shares can unlock a life-changing passive income over time, as Royston Wild explains.

Read more »